© 2026 FLARE THERAPEUTICS INC. ALL RIGHTS RESERVED.
Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Flare Therapeutics Presents Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at SITC 2025 40th Anniversary Annual Meeting
Flare Therapeutics to Participate in Upcoming Investor Conferences in November
Flare Therapeutics to Present Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at Upcoming SITC 2025 40th Anniversary Annual Meeting
Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
Flare Therapeutics to Participate in Upcoming Investor Conferences in September
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
Flare Therapeutics to Participate in Jefferies Global Healthcare Conference
Flare Therapeutics to Present at Two Upcoming December Conferences
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Flare Therapeutics to Present at Two Upcoming November Conferences
Flare Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy
Flare Therapeutics to Present Immune Profiling Data from Urothelial Cancer Patients Treated with Anti-PD1 Therapy at AACR 2024 Annual Meeting
Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma--Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting
--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting
Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer
FX-909 is a first-in-class small molecule inhibitor of the PPARG transcription factor for the potential treatment of advanced urothelial carcinomaFlare Therapeutics Presents Novel, AI-Based Method Identifying Luminal Subtype of Urothelial Cancer Supporting Lead Asset FX-909 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Flare Therapeutics to Present Biomarker Data for Clinical Candidate FX-909 at 2023 AACR-NCI-EORTC International Conference
Flare Therapeutics Named to Inc. Magazine’s Annual List of Best Workplaces for 2023
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting
Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Michael L. Meyers, M.D., Ph.D. to join as Chief Medical Officer; Daphne Karydas promoted to President and Chief Financial Officer; Michaela Bowden, Ph.D., promoted to Chief Development Officer; and Jigar Raythatha joins the Board of DirectorsFlare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncologyFlare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting
Robert Sims, Ph.D., Chief Scientific Officer and co-founder of Flare Therapeutics, will present the discovery of its clinical candidate, FX-909, at the AACR Annual Meeting in Orlando, FLFlare Therapeutics to Present at Guggenheim Healthcare Talks Oncology Day
Robert Sims, Ph.D., Chief Scientific Officer and co-founder at Flare Therapeutics, will present a company overview at the upcoming Guggenheim Healthcare Talks Oncology Day in New York, NYFlare Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NYFlare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approachFlare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium
Data highlight the potential for novel small molecule inhibitors of key transcription factors to target and effectively treat advanced UCFlare Therapeutics Appoints Amit Rakhit, M.D. as President and Chief Executive Officer
Biopharma industry veteran to lead advancement of company’s transcription factor-focused pipeline into clinical stage and expand discovery effortsFlare Therapeutics Appoints Adrian Jubb as Chief Medical Officer
Dr. Jubb’s research and clinical development experience strongly positions company for clinical excellence in advancing precision oncology pipelineFlare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation
Company expands leadership team across business and science as it advances precision oncology pipelineFlare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors
Company has pioneered ‘switch site’ approach to uncover druggable regions within well validated, but elusive, transcription factors that are master regulators of gene expressionThe links below will direct you to an external website. Access to their content and articles is subject to the terms, conditions and privacy policies of the external publisher.
Cancer Discovery
First-of-Its-Kind PPARG Inhibitor Shows Compelling Activity
The Clinical Trail Vanguard
Flare Therapeutics Reveals FX-909 Phase 1 Study Results
Nature Biotechnology
Big pharma seduced by transcription factors again. What has changed?
Urology Times
Phase 1B trial of PPARG inhibitor launches in urothelial carcinoma
Fierce Biotech
Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact
The pharmaletter
One to Watch – Flare Therapeutics
Fierce Biotech
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Fierce Biotech
With a new approach, startup Flare Therapeutics may solve the transcription factor puzzle.
Global Genes
Flare Launches with $82 Million to Advance Novel Drug Discovery Approach for Transcription Factors
SHINING LIGHT ON PROGRESS
Contact Us
Investors
Sarah McCabe
investorrelations@flaretx.com
Media
Timothy Cockroft
media@flaretx.com
This links to an external website.